MEDIR is a specialty pharmaceutical company, seeking to address the areas of high unmet medical needs in:
1. inducing mild sedation in a safe, convenient and needle free way; and
2. offering a treatment for acute epileptic seizure control outside a hospital setting, that is fast, efficacious and easy adminstered.
The company has developed nasal sprays (trademark: Nazolam) containing midazolam, a compound that currently needs to be administered by intravenous injection for predicitive results. 

Device picture: property and courtesy of Aptar Pharma

Nazolam news

Nazolam news

In a survey among epileptics/care givers, it was concluded that the nasal spray has been received with a lot of…

Read More

Contact us